Eli Lilly & Co. struck a deal worth up to $1.9 billion with privately held biotech Ascidian Therapeutics Inc. to develop treatments for rare kidney diseases, expanding the obesity drugmaker’s push ...
The most recent developments in the field of A-to-I RNA modification, with a special emphasis on the roles of A-to-I in the genesis and progression of cancer. Adenosine-to-inosine (A-to-I) RNA editing ...
Emerging gene editing platforms are revolutionizing precision medicine, enabling safe and effective genetic modifications for ...
A research team from the School of Biomedical Sciences at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), ...
The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular ...
Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney Diseases
Eli Lilly has expanded its genetic medicines pipeline and capabilities, agreeing to partner with Ascidian Therapeutics to develop RNA exon editors intended to treat inherited kidney diseases, through ...
Wave Life Sciences (WVE) was not the only developer of RNA editing therapies to show significant stock gains from its historic proof-of-mechanism for its RNA editing platform, shown recently in the ...
Boston, Massachusetts-based biotech Ascidian Therapeutics on Wednesday announced a research deal and a licensing agreement worth up to $1.9B with Eli Lilly (LLY) to develop and market kidney disease ...
Eli Lilly is widening its push beyond obesity and diabetes, signing a deal worth up to $1.9 billion with privately held Ascidian Therapeu ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results